Effect of the aggregation state of amyloid-beta (25-35) on the brain oxidative stress in vivo.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2024
2024
Historique:
received:
08
04
2024
accepted:
27
08
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
Aggregation pathway of amyloid-β (25-35) in water affects the oxidative stress in the brain observed after administration of aggregated peptide in animals in vivo. Our studies on peptide aggregation ex situ prior to injection suggest that from the onset of peptide incubation in aqueous media, all samples exhibit the formation of fibril-like aggregates, characterized by a significant amount of β-sheets. This induces significant oxidative stress in vivo as observed for up to 60 min of peptide aggregation time. As the aggregation advances, the fibril-like aggregates become longer and intertwined, while the amount of β-sheets does not change significantly. An injection of such large, thick, and entangled aggregates in the animal brain results in a drastic increase in oxidative stress. This may be related to the number of activated microglia that initiate a sequence of inflammatory responses in the presence of large, highly interconnected fibrils.
Identifiants
pubmed: 39471144
doi: 10.1371/journal.pone.0310258
pii: PONE-D-24-13509
pmc: PMC11521274
doi:
Substances chimiques
Amyloid beta-Peptides
0
Peptide Fragments
0
Protein Aggregates
0
amyloid beta-protein (25-35)
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0310258Informations de copyright
Copyright: © 2024 Kozina et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Biochim Biophys Acta. 2010 Jul;1804(7):1405-12
pubmed: 20399286
Biophys J. 2006 Sep 1;91(5):1638-47
pubmed: 16766615
Biophys J. 2012 Aug 8;103(3):576-586
pubmed: 22947874
Evid Based Complement Alternat Med. 2023 Feb 21;2023:8056462
pubmed: 36865743
Biochim Biophys Acta. 2013 Oct;1828(10):2328-38
pubmed: 23746423
Physiol Behav. 2004 Feb;80(5):647-55
pubmed: 14984798
Sci Rep. 2019 Feb 25;9(1):2689
pubmed: 30804528
Eur J Pharmacol. 1997 Jan 14;319(1):1-4
pubmed: 9030890
FEBS Lett. 2007 Mar 20;581(6):1161-5
pubmed: 17328898
J Am Chem Soc. 2022 Aug 17;144(32):14614-14626
pubmed: 35917596
Neurosci Behav Physiol. 2006 Jan;36(1):101-6
pubmed: 16328175
J Struct Biol. 2005 Jan;149(1):30-7
pubmed: 15629655
J Neural Transm (Vienna). 2010 Aug;117(8):949-60
pubmed: 20552234
Eur J Pharmacol. 2012 Jun 15;685(1-3):74-80
pubmed: 22542664
J Med Chem. 2004 Aug 12;47(17):4231-8
pubmed: 15293994
Biochemistry. 1994 Feb 15;33(6):1345-50
pubmed: 8312252
Exp Neurol. 2010 Mar;222(1):6-9
pubmed: 20043907
J Neurosci Res. 2002 Nov 1;70(3):474-83
pubmed: 12391608
Neurosci Res. 2009 Feb;63(2):129-37
pubmed: 19084561
Curr Pharm Des. 2010;16(25):2837-50
pubmed: 20698819
Langmuir. 2014 Mar 25;30(11):3191-8
pubmed: 24575974
Neuropeptides. 2014 Jun;48(3):153-9
pubmed: 24703968
Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):E3095-103
pubmed: 26038575
Neurochem Int. 2008 May;52(6):1114-24
pubmed: 18207612
PLoS Comput Biol. 2007 Sep;3(9):1727-38
pubmed: 17941703
Neuropathology. 2004 Sep;24(3):194-200
pubmed: 15484697
Curr Protein Pept Sci. 2010 Feb;11(1):54-67
pubmed: 20201807
Free Neuropathol. 2020;1:
pubmed: 33345256
J Neuroinflammation. 2004 Jul 30;1(1):14
pubmed: 15285801
J Neurosci. 2001 Feb 15;21(4):1179-88
pubmed: 11160388
Neuropeptides. 2018 Feb;67:56-62
pubmed: 29174415
J Biosci. 2009 Jun;34(2):293-303
pubmed: 19550045
Biochem Biophys Res Commun. 2007 Oct 5;361(4):916-21
pubmed: 17679138
Biophys J. 2004 Jul;87(1):622-30
pubmed: 15240495
Front Neurosci. 2022 Aug 12;16:951128
pubmed: 36033617
Psychopharmacology (Berl). 2014 Sep;231(17):3293-3312
pubmed: 24481566
Neurosci Behav Physiol. 2003 Feb;33(2):95-8
pubmed: 12669778
J Alzheimers Dis. 2012;30(3):505-22
pubmed: 22430532
J Neurosci. 1993 Apr;13(4):1676-87
pubmed: 8463843
Pharmacol Biochem Behav. 2011 Mar;98(1):67-75
pubmed: 21163295
Exp Neurol. 2006 Aug;200(2):496-508
pubmed: 16626708
ACS Chem Neurosci. 2012 Nov 21;3(11):952-62
pubmed: 23173074
Phys Chem Chem Phys. 2010 Apr 14;12(14):3622-9
pubmed: 20336261
Life Sci. 2002 Jan 4;70(7):833-41
pubmed: 11833745
Chem Rev. 2012 Oct 10;112(10):5147-92
pubmed: 22813427
Neurochem Res. 2004 Apr;29(4):729-33
pubmed: 15098934
J Biol Chem. 2000 Aug 18;275(33):25109-15
pubmed: 10825171
J Neurochem. 1995 Jan;64(1):253-65
pubmed: 7798921
Prog Neurobiol. 2000 Dec;62(6):633-48
pubmed: 10880853
Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3270-4
pubmed: 8159737
Oxid Med Cell Longev. 2018 Aug 1;2018:1358057
pubmed: 30154946
Mol Psychiatry. 2021 Oct;26(10):5481-5503
pubmed: 34456336
J Neurosci. 2011 Nov 2;31(44):15703-15
pubmed: 22049413
J Alzheimers Dis. 2018;62(3):1345-1367
pubmed: 29562527
J Alzheimers Dis Rep. 2020 Jun 16;4(1):175-183
pubmed: 32715278
Neuron. 1996 Sep;17(3):553-65
pubmed: 8816718
Eur J Pharmacol. 2009 Aug 15;616(1-3):122-7
pubmed: 19540227
Biochemistry. 2013 Aug 6;52(31):5176-83
pubmed: 23837615
Neurosci Lett. 2010 Jan 4;468(2):151-5
pubmed: 19879921
Cold Spring Harb Perspect Med. 2012 May;2(5):a006270
pubmed: 22553493
J Neurosci Res. 2003 Jan 1;71(1):110-20
pubmed: 12478619
Ibrain. 2022 Feb 22;8(1):37-47
pubmed: 37786418
Sci Rep. 2018 Jan 15;8(1):765
pubmed: 29335442
Sci Rep. 2021 Nov 9;11(1):21990
pubmed: 34754013
Brain Res. 2016 Jul 1;1642:327-335
pubmed: 27071547
Exp Neurol. 2010 Jan;221(1):26-37
pubmed: 19751725
Int J Biol Macromol. 2019 Aug 1;134:1022-1037
pubmed: 31128177